Happy Thanksgiving from Aclarion! As we reflect on the year, we’re deeply grateful for the patients, clinicians, imaging partners, and investors who believe in our mission to bring greater clarity to chronic low back pain. Wishing everyone a restorative holiday. $ACON

We’re excited to welcome Jason Brosniak as Aclarion’s new Commercial Director, Eastern U.S.! He joins at a pivotal time as we expand adoption of Nociscan and deepen payer engagement. Join us in welcoming him to the team! bit.ly/44JyHkB $ACON #PainManagement

We’re proud to share that Nociscan is featured in the Special Pain Issue of the ISASS. Being included is a meaningful acknowledgment of the momentum building for more objective tools to evaluate chronic low back pain. investors.aclarion.com/news/aclarion-… $ACON #PainManagement

We’re looking forward to the 19th NYC-MISS Symposium led by course directors Dr. Roger Härtl and Dr. Luiz Pimenta! If you’ll be attending and would like to connect, reach out to us at [email protected]. See you in NYC! $ACON #NYCMISS

✨ This year brought meaningful progress. As we look ahead, we remain focused on advancing objective insights with Nociscan to help clinicians better understand chronic low back pain and support more personalized care. Wishing everyone a joyful holiday season.

Patient enrollment milestone - Northwestern Medicine and Scripps Health have enrolled their first patients in the company’s pivotal CLARITY trial also intended to support future reimbursement discussions. Read the press release: bit.ly/4sucYHA $ACON

Aclarion provides an update on progress in 2025 and outlook for 2026. We had an impressive year with significant NOCISCAN volume growth, the launch of our pivotal CLARITY trial, new hires to support commercial growth and more. Read the full release: bit.ly/4qc0rXN $ACON

Aclarion strengthens its balance sheet and extends cash runway into 2028. We are focused on expanding adoption of Nociscan, deepening clinical evidence, and building strategic relationships that drive durable growth for patients. Read more: bit.ly/3NjPqVV $ACON

We’re looking forward to Spine: Base to Summit and the thoughtful conversations this meeting always brings to the spine community. CEO, Brent Ness, will be available for 1:1 meetings. To discuss incorporating Nociscan into your practice, please send us a message! $ACON

We will be at the #SelbySpine Conference next week! Looking forward to Dr. Nunley’s presentation during the Tech Talks Session where he will be highlighting Nociscan and the value of MR Spectroscopy, including his own patient examples. Connect with us at [email protected] $ACON

We’re pleased to welcome Source Healthcare as the newest high-volume practice offering Nociscan in the greater Los Angeles area. This collaboration expands patient access and supports real-world evidence efforts led by Dr. Tim Davis. Read more: bit.ly/4rxHSOg $ACON

In an exclusive interview with Stocktwits, CEO Brent Ness outlines Aclarion’s 2026 focus - advancing the CLARITY trial, expanding real-world evidence, UK coverage, scanner access, and reimbursement progress to drive adoption. Read more: bit.ly/3MqnBet $ACON

Our 2026 Shareholder Letter from Executive Chairman Jeff Thramann is live, providing a detailed overview of Aclarion's progress, key milestones, and strategic priorities for 2026. Read the full update on our continued momentum and what’s ahead: bit.ly/49YW90t $ACON

Nociscan turns MRI spectroscopy data into actionable insights using cloud-based AI. Aclarion CEO Brent Ness explains how it supports more informed clinical decision-making to improve outcomes for chronic low back pain on Empowered Patient Podcast: bit.ly/3Zt9BUm $ACON

Breakthrough healthtech doesn’t commercialize by science alone. Aclarion CEO Brent Ness shares a blueprint with Medical Design & Outsourcing for moving AI-driven medtech from innovation to standard of care. Read more: bit.ly/4l3HNjr $ACON

In a new interview with CEOCFO Magazine, CEO Brent Ness explains how Nociscan uses biomarker analysis to identify painful discs more accurately, aiming to improve treatment decisions and potentially reduce unnecessary costs. Read the interview here: bit.ly/3Oy7HPZ $ACON

We're looking forward to #SpineSummit in Phoenix, AZ and meeting with industry peers who are shaping the future of spine care. If you want to learn more about how Nociscan provides objective, noninvasive insights into disc-level pain biomarkers, send us a message to connect $ACON

CEO Brent Ness offers perspective in Orthopedic Design & Technology, drawing an important parallel between cardiology’s evolution & what’s needed in spine care today. Read insights on how applying that same framework to chronic low back pain could improve outcomes: bit.ly/4cbVwSH $ACON

In a new interview, CEO Brent Ness discusses our approach to treating chronic lower back pain and highlights how Nociscan’s biomarker analysis helps identify painful discs to support better treatment planning. Subscribe for free: bit.ly/4rFLMFc $ACON

Aclarion CEO Brent Ness will be attending #LSIUSA26, March 16-20, 2026, in Dana Point, CA. He will be available for 1x1 meetings. Please email: [email protected] to schedule. Read more: bit.ly/4rohohz $ACON